When tumor classification as either ER positive or negative was considered, 14 (8%) tumor samples were differently classified when comparing visual scoring to the slide-scanner, and 16 (9%) cases when visual scoring was compared with the point-of-care microscope (Table 2). This evidence concerns the gene ESR1 and neoplasm.